NTLA

Intellia Therapeutics, Inc

12.24

USD

+0.10

+0.86%

Sep 21, 15:13 UTC -4

Open

Intellia Therapeutics, Inc Profile

About

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.?

Info & Links

CEO

John M. Leonard

Headquarters

40 Erie Street, Suite 130
Cambridge, MA 02139, UNITED STATES

Auditor

Deloitte & Touche LLP

Share holders

Employees

377

Intellia Therapeutics, Inc Statistics

Valuation Measures

Market Capitalization²

1.72B

Enterprise Value

1.61B

Enterprise Value/EBITDA(ttm)

-3.94

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

28.59

Price to Book(mrq)

2.33

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-672.16%

Profit Margin(ttm)

-795.78%

Return on Equity(ttm)

-57.79%

Return on Invested Capital(ttm)

-57.96%

Return on Assets(ttm)

-47.29%

Income Statement

Revenue(ttm)

59.51M

Revenue Per Share(ttm)

0.42

Gross Profit(ttm)

59.51M

EBITDA(ttm)³

-408.24M

Net Income Available to Common(ttm)

-399.98M

Diluted EPS(ttm)

-3.36

Share Statistics

Beta (5Y Monthly)

1.82

52-Week Change

-21.46%

S&P 500 52-Week Change

17.10%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

140.13M

Dividend Yield

0.00%

Float⁴

135.22M

% Held by Insiders

3.50%

% Held by Institutions

88.77%

Balance Sheet

Total Cash(mrq)

437.76M

Total Cash Per Share(mrq)

3.12

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

6.65%

Quick Ratio(mrq)

6.65%

Book Value Per Share(mrq)

5.20

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.50

Free Cash Flow(ytd)

-202.26M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.